Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 29, 2023

Evommune, Accutar to discover drug candidates for chronic inflammatory diseases

Evommune has entered into a new strategic partnership with Accutar Biotechnology to discover new small-molecule drug candidates for chronic inflammatory diseases.

Continue
The partnership will focus on the development of next-generation therapies. Credit: Lucas Vasques on Unsplash.
November 28, 2023

Sernova secures ODD and RPDD for Haemophilia A programme

The programme aims to substitute Factor VIII (FVIII), a crucial protein for blood clotting that is lacking in individuals with Haemophilia A. Credit: Corey Ryan Hanson from Pixabay.
November 27, 2023

Mesoblast files applications with US FDA for HLHS therapy

Mesoblast has filed applications for orphan drug and rare paediatric disease designations for Revascor to treat congenital heart disease hypoplastic left heart syndrome. Credit: StockSnap from Pixabay.

Contracts

December 14, 2022

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Micrograph of psoriasis vulgaris. Credit: Jenny Giang, Marc A. J. Seelen, Martijn B. A. van Doorn, Robert Rissmann,Errol P. Prens and Jeffrey Damman/ commons.wikimedia.org.

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Kite, Refuge sign license deal for gene expression platform for blood cancers

Deals

Deals October 2, 2023

Novartis offloads ophthalmology assets for $2.5bn

Pharmaceutical Business Review

Eli Lilly and Company completes acquisition of Versanis Bio

GSK acquires pharma firm Bellus Health for $2bn

EdgeCap Partners buys majority stake in Comac Medical

Popular

  1. Boehringer Ingelheim announces acquisition of T3 Pharmaceuticals
  2. US FDA approves Valneva’s vaccine against chikungunya virus
  3. BeiGene to acquire global license to Ensem Therapeutics’ CDK2 inhibitor
  4. NeoImmuneTech receives orphan drug status for NT-I7 to treat ARS
  5. Almirall obtains approval from EC for atopic dermatitis therapy

PRESS RELEASES

Gerresheimer: Green Electricity from Wind for German Production Sites
Gerresheimer: Green Electricity from Wind for German Production Sites
Groundbreaking Ceremony for Plant Expansion in Querétaro, Mexico
Groundbreaking Ceremony for Plant Expansion in Querétaro, Mexico
Safety First: Tosoh Bioscience Transforms Gene Therapy with Innovative AAV Analysis Technique
Safety First: Tosoh Bioscience Transforms Gene Therapy with Innovative AAV Analysis Technique
Gerresheimer Awarded EcoVadis Gold Status Again
Gerresheimer Awarded EcoVadis Gold Status Again
RWS at the 2023 CAHP Conference – 23-25 October in Palm Desert, California
RWS at the 2023 CAHP Conference – 23-25 October in Palm Desert, California

Suppliers

Whitepapers

Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation